Yu Jonathan Yen-Wen sold $8K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 100 shares of Disc Medicine, Inc. (IRON) at $82.50 on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Jul 9, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

A COO open-market sale of 100 shares at $82.50 under a pre-arranged 10b5-1 plan is generally treated as routine compliance rather than a fundamental update.

02

Market read

Traders may note the filing for completeness, but it is unlikely to drive a material repricing without additional corroborating catalysts.

03

What to watch

The article provides only one small sale; it does not include any concurrent buys, option exercises, or broader insider activity trends that would strengthen inference.

Relevance 2/10Novelty 3/10Timing: new Form 4 filed 2026-07-09 for a 2026-07-07 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold 100 shares at $82.50 on 2026-07-07 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely minimal to no immediate price impact; any effect would be sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with modest size ($8,250) and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single small 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal expectations of near-term risk, so traders may watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Disc Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRONHighAI 9/10

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e

$IRONHighAI 9/10

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on

$IRONHighAI 8/10

Why is Disc Medicine stock sliding today?

Disc Medicine (IRON) stock fell 1.0% in pre-market trading after pricing a $450M public offering of 6M shares at $75 each, a discount to recent prices. The offering, with potential for additional shares, may dilute existing holders. Proceeds will fund clinical development and general corporate purposes. Analysts recently raised price targets following positive trial results, but insiders have been net sellers.